3,400 Shares in Ultragenyx Pharmaceutical Inc (RARE) Acquired by A.R.T. Advisors LLC

A.R.T. Advisors LLC bought a new stake in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) during the fourth quarter, Holdings Channel reports. The institutional investor bought 3,400 shares of the biopharmaceutical company’s stock, valued at approximately $239,000.

Other large investors have also made changes to their positions in the company. First Mercantile Trust Co. increased its stake in shares of Ultragenyx Pharmaceutical by 1.7% in the third quarter. First Mercantile Trust Co. now owns 2,339 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 39 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 9.4% in the third quarter. Pacer Advisors Inc. now owns 2,237 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 192 shares in the last quarter. BlackRock Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 6.8% in the third quarter. BlackRock Inc. now owns 4,244 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 271 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the third quarter. Teachers Advisors LLC now owns 173,265 shares of the biopharmaceutical company’s stock worth $12,291,000 after buying an additional 510 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Ultragenyx Pharmaceutical by 0.9% in the third quarter. California State Teachers Retirement System now owns 76,245 shares of the biopharmaceutical company’s stock worth $5,409,000 after buying an additional 700 shares in the last quarter. 96.35% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) opened at 85.07 on Tuesday. Ultragenyx Pharmaceutical Inc has a one year low of $46.52 and a one year high of $91.35. The stock has a 50 day moving average of $79.49 and a 200-day moving average of $73.19. The stock’s market cap is $3.55 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by $0.03. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.05 million. The company’s revenue was up 4900.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.42) EPS. Analysts anticipate that Ultragenyx Pharmaceutical Inc will post ($7.11) EPS for the current year.

Your IP Address:

A number of brokerages have commented on RARE. Citigroup Inc downgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to a “sell” rating in a research report on Wednesday, November 30th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, January 12th. Wedbush began coverage on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 17th. They issued an “outperform” rating and a $88.00 price objective on the stock. Jefferies Group LLC reissued a “buy” rating and issued a $109.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 17th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $96.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the stock. Ultragenyx Pharmaceutical presently has an average rating of “Buy” and an average target price of $90.46.

In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 12,000 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $90.10, for a total transaction of $1,081,200.00. Following the completion of the sale, the chief financial officer now owns 67,887 shares in the company, valued at $6,116,618.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Theodore Alan Huizenga sold 2,500 shares of the business’s stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $86.34, for a total transaction of $215,850.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,500 shares of company stock valued at $2,258,730. Insiders own 10.10% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024707/3400-shares-in-ultragenyx-pharmaceutical-inc-rare-acquired-by-a-r-t-advisors-llc.html

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.